Compare ELA & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | SENS |
|---|---|---|
| Founded | 1965 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.3M | 496.0M |
| IPO Year | 1995 | 2014 |
| Metric | ELA | SENS |
|---|---|---|
| Price | $12.18 | $9.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $25.00 | $14.20 |
| AVG Volume (30 Days) | 90.7K | ★ 588.8K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.38 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $241,021,362.00 | $16,389,000.00 |
| Revenue This Year | $11.22 | $82.21 |
| Revenue Next Year | N/A | $55.63 |
| P/E Ratio | $24.92 | ★ N/A |
| Revenue Growth | ★ 33.62 | 19.85 |
| 52 Week Low | $7.14 | $0.41 |
| 52 Week High | $29.68 | $10.48 |
| Indicator | ELA | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 31.99 | 63.39 |
| Support Level | $11.59 | $5.36 |
| Resistance Level | $14.01 | N/A |
| Average True Range (ATR) | 0.56 | 0.44 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 9.63 | 73.21 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.